Skip to main content

Table 1 Mean (SD) and differences in demographic characteristics, pain-related fear, outcome variables, and cost components at an eight-week baseline period per treatment group

From: Is exposure in vivo cost-effective for chronic low back pain? A trial-based economic evaluation

 

Mean (SD)

Mean difference (95 % CI)

Variables

GA (n = 31)

EXP (n = 31)

EXP versus GA

Age (years)

45.45 (8.42)

47.13 (9.58)

−1.67

(-2.90 to 6.26)

Gender (% female)

50 %

50 %

  

Education (%)

   

(-0.51 to 0.13)

 Low

41.9 %

45.2 %

  

 Intermediate

41.9 %

54.8 %

 High

16.1 %

0 %

QBPDS (0-100)b

53.53 (12.79)

55.02 (11.41)

1.48

(-4.67 to 7.64)

Utility (0-1)b

0.60 (0.07)

0.58 (0.05)

−0.02

(-0.06 to 0.01)

Health care costsa

68.56 (30.27)

65.78 (38.68)

−3.00

(-94.00 to 99.00)

Patient and family costsa

332.44 (94.59)

367.74 (84.98)

35

(-224.00 to 268.00)

Productivity lossa

1,126.98 (355.07)

754.83 (255.86)

−372

(-1,205.00 to 456.00)

Total costs a

1,529.32 (371.80)

1,204.73 (282.12)

−325

(-1,301 to 586)

  1. GA graded activity, EXP gradual exposure, QBPDS Quebec Back Pain Disability Score, QALYs quality-adjusted life years. Costs are in euros and per patient
  2. aDifference in mean (95 % confidence interval) derived using bootstrapping (1,000 replications)
  3. bDifference in mean (95 % confidence interval) derived using independent t-tests or chi-square tests